Ensign Peak Advisors, Inc Kinnate Biopharma Inc. Transaction History

Ensign Peak Advisors, Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$7.43 - $13.0 $39,104 - $68,419	-5,263 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$7.73 - $17.99 $75,267 - $175,168	-9,737 Reduced 64.91%	5,263 $59,000
Q4 2020 Feb 12, 2021	BUY	$36.35 - $45.25 $545,250 - $678,750	15,000 New	15,000 $597,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.